文献速递消化道肿瘤放疗姑息放疗与转移瘤

立体定向体部放疗序贯替吉奥治疗体能状态差的局部晚期胰腺癌:单臂2期试验

Stereotactic body radiation therapy with sequential S-1 for patients with locally advanced pancreatic cancer and poor performance status: An open-label, single-arm, phase 2 trial.
PubMed 文献 · Radiother Oncol · 2021-07-16

这项开放标签单臂2期试验纳入63例ECOG评分≥2的局部晚期胰腺癌患者,接受35-40 Gy/5次SBRT后序贯替吉奥口服6周期。主要终点1年总生存率为73.0%,中位OS 14.4个月,中位PFS 10.1个月,28.6%患者出现3级毒性,腹痛和生活质量有显著改善。

要点

  • ECOG≥2的局部晚期胰腺癌患者接受SBRT序贯替吉奥,1年OS率达73.0%。
  • 中位OS 14.4个月,中位PFS 10.1个月,3级毒性发生率28.6%。
  • 基线生活质量较差者治疗后健康状态和疼痛缓解改善更明显。

核心结论

  • SBRT序贯替吉奥在体能状态差的局部晚期胰腺癌患者中显示出有前景的疗效和可接受的毒性。

研究设计与样本

  • 开放标签、单臂、2期试验,纳入63例组织学和影像学确诊的局部晚期胰腺癌且ECOG评分≥2的患者。
  • 放疗剂量35-40 Gy/5次,SBRT后1个月开始替吉奥80 mg/m2口服每日两次,服28天休14天,共6周期。
  • 主要终点为1年总生存率,次要终点包括OS、PFS、治疗相关毒性和生活质量。

主要发现

  • 63例患者全部死亡,无失访,中位随访15.8个月(95%CI 12.9-18.7个月)。
  • 1年OS率为73.0%(46/63,95%CI 67.4%-78.6%)。
  • 中位OS为14.4个月(95%CI 13.2-15.6个月),中位PFS为10.1个月(95%CI 9.7-10.5个月)。
  • 18例(28.6%)发生3级毒性。
  • QLQ-C30显示腹痛显著改善,基线整体健康状况较差者治疗后健康状态和疼痛缓解改善更大。

关键数值与推荐

  • 入组标准为组织学和影像学确诊的局部晚期胰腺癌且ECOG评分≥2分(由两名独立医师判定)。
  • 放疗剂量范围为35-40 Gy/5次。
  • 替吉奥剂量为80 mg/m2口服每日两次,服28天休14天,共6周期,SBRT后1个月开始。
  • 主要终点1年OS率为73.0%(95%CI 67.4%-78.6%),中位OS 14.4个月(95%CI 13.2-15.6个月),中位PFS 10.1个月(95%CI 9.7-10.5个月)。
  • 3级毒性发生率为28.6%(18/63)。

临床怎么用

  • 对于ECOG评分≥2、通常被临床试验排除的局部晚期胰腺癌患者,可考虑SBRT序贯替吉奥方案。
  • 该方案在体能状态差的患者中显示出可接受的毒性和生存获益,尤其对基线生活质量较差者有更明显的健康状态和疼痛改善。

局限性

  • 单臂设计,无对照组,结论需随机对照试验进一步验证。
  • 样本量63例,随访期内全部患者死亡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The optimal treatment for a particularly neglected group of patients with locally advanced pancreatic cancer (LAPC) and poor performance status, who are usually excluded from most clinical trials, is required. Therefore, we aim to investigate the efficacy and safety of stereotactic body radiation therapy (SBRT) with sequential S-1 for those patients. METHODS: Eligible patients had histologically and radiographically confirmed LAPC and ECOG performance status of 2 or more points determined by two independent physicians. Radiation doses ranged from 35-40 Gy/5f. S-1 was taken orally, twice daily, at a dose of 80 mg/m2 for 28 days, followed by a 14-day interval, which repeated for 6 cycles and was initiated one month after SBRT. The primary endpoint was 1-year overall survival (OS). The secondary endpoints were OS, progression free survival (PFS), treatment-related toxicity and quality of life. The study was registered at ClinicalTrials.gov: NCT02704143. RESULTS: Sixty-three patients were enrolled. At the time of data cut-off, all patients died. No patients were lost to follow-up. Median follow-up was 15.8 months (95%CI 12.9-18.7 months). One-year OS was noted in 46 of 63 patients (73.0%, 95%CI 67.4%-78.6%). The median OS and PFS was 14.4 (95%CI 13.2-15.6 months) and 10.1 months (95%CI 9.7-10.5 months) respectively. Eighteen patients (28.6%) had grade 3 toxicity. According to Quality of Life Questionnaire-Core 30, significant improvements of abdominal pain were found, and patients with poorer baseline global health status had greater improvement of health status and pain relief after treatment. CONCLUSIONS: SBRT with sequential S-1 shows promising efficacy and acceptable toxicity in poor performance status patients with LAPC.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Zhu X, Cao Y, Lu M, et al. Stereotactic body radiation therapy with sequential S-1 for patients with locally advanced pancreatic cancer and poor performance status: An open-label, single-arm, phase 2 trial. Radiother Oncol. 2021. PMID: 34274393. doi:10.1016/j.radonc.2021.07.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。